Oncology KnowledgeBASE
New Medicine
Product Designation:
Breastin
Descirption :
Breastin is a cold patented extract obtained from Nerium oleander with potential anticancer activity against some tumors.
Primary Developer:
Applied Company For Therapeutic Preparations L.C.C. in collaboration with Oncotest LLC. Freiburg-Germany.
Product Specifications:
Therapeutic Indications: Breast, lung, prostate, pancreas and colorectal
adenocarcinomas
Therapeutic Category…….Targeted drug therapy
Drug Category ………… A fraction from N. Oleander that contains mainly two
glycosides plus few other compounds.
Mechanism………………Antioncogenic, cell- cycle inhibition, cytotoxic effects
are induced by the inhibition of the plasma bound Na+/
K+- ATPase.
Mechanism Details…… Breastin inhibits cell division at the S- phase. In addition, it
has antioncogenic activity against some oncogens., the
cytotoxic effects are induced by the inhibition of the plasma
membrane bound Na+/ K+ ATPase as known for cardiotonic
effects. These mechanism of actions are supported by clinical
evidence, which demonstrate that Breastin is specific in its
activity against some cancers such as breast, lung, pancreas,
prostate lung adenocarcinomas.
Preclinical History:
Large cell lung, prostate, colon, uterus, pleuramesothelioma cell
lines are particularly sensitive to cytotoxic effects of Breastin.
Breastin is also potent against melanoma, bladder, renal and
ovarian cell lines. Breastin cause profound inhibition of tumor
growth in a variety of in vivo models, leading to regression
of large cell lung, colon, breast and prostate adenocarcinomas.
Breastin is a potent and selective preparation against some tumors.
It blocks cell- cycle progression and induces apoptosis in a diverse
range of human tumor types. Breastin profoundly inhibit tumor
growth in a variety of in vivo models, leading to regression of
B- 16 melanoma, Lewis- lung carcinoma and 180-sarcoma.
Breastin can be used as a supplementary medication to cancer
chemo-, hormone and/ or radiotherapy to restore and/ or
ameliorate the immune system of the patient and/ or to decrease
side effects and increase the antitumor effect of radiotherapy and
chemotherapeutics, particularly when used in combination with
taxol, adriamycin, cisplatin, 5-FU, alimta, cyclophosphamide,
mitomycin-C, navelbine, taxotere and topotecan, respectively, and
its use in the manufacture of a medication for the treatment of one
or more cancers of bladder, liver, ovary, pancreas, testicle, uterus
and vagina as well as pleuramesothelium and Hodgkin’s
lymphoma.
Administration Route: IM and OR.
Toxicities: Slight to moderate rise in temperature, nausea in 7- 10% of patients
plus diarrhea in 3-8 patients used Breastin.
Cancer indication: Solid tumors, breast cancer, colon cancer, lung cancer, prostate
cancer.
Can be used as a supplementary medication that can be taken
Alongside with some chemotherapy, radiotherapy and/ or
Hormonal therapy against some tumors.
CLINICAL STATUS BY INDICATION
Indication: Solid tumors
Latest Status: Phase II
Clinical History: In March 1988, dose esculation phase I clinical trial that will adminis.
Breastin 3- 4 mg IM to patients with solid tumors and 15- 20 mg OR as
an adjuvant route. The trial evaluates safety and tolerability of Breastin.
Indication: Solid tumors, including breast and colorectal tumors.
Clinical History: During the period between 1988- 2000 Breastin was clinically tested
on more than 283 patients (Phase II) suffering from different types
of tumors including Breast, colorectal, prostate, lung, skin, osteo-
sarcoma, larynx, bladder, glioblastoma...etc ,where Breastin
was administered 3- 4 mg using IM route and 15- 2 0 mg OR as an
adjuvant therapy. The trial was designed to assess how well Breastin
works, as well as to continue phase (I) safety assessments in a larger
group of patients.
More patients were enrolled in Breastin treatment from 2001 up to
date 2011 (more than 300 patients). These cases include maily
the 4 types of cancer responded to Breastin as shown in Phase II
clinical studies.
During the period between 2005- 2019 a total of more than 637
Cancer patients were treated with Breastin (lung, breast, colorectal,
Prostate…etc). Again Breastin showed remarkable potential effect
Against some cancers such as Breast, Colon, prostate, lung and
Pancreas.
This product was adopted by a Swiss-based company named Research Genetic Cancer Center (RGCC) since 2017 up to date. They are using it with other natural biological substances/ extracts (Onconomics Extracts). It focuses on testing using three methods: testing for direct effect on anti-cancer treatment, stimulating the immune system and inhibiting proliferation signals in the cancer cells that stimulate them to grow. The results are every encouraging.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- drug study guide for nplex clincal
- possible side effects of folfox leucovorin 5
- national cancer expert reference group public and private
- introduction and welcome cancer
- bowel cancer quality performance indicators descriptions
- oncology mcq
- the scottish government health directorates
- proposed colorectal cancer systemic anti cancer therapy
- gov
- oncology knowledgebase